{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 42562,
    "metadata": {
        "identifiers": {
            "doi": "10.1016/s0140-6736(20)30305-6",
            "arxiv": null,
            "isbn": null,
            "doc_id": null,
            "url": "http://www.thelancet.com/article/S0140673620303056/pdf"
        },
        "title": "Reducing mortality from 2019-nCoV: host-directed therapies should be an option",
        "author": "Alimuddin Zumla, David S Hui, Esam I Azhar, Ziad A Memish, Markus Maeurer",
        "date": 2020,
        "affiliations": [
            "National Institutes of Health Research senior investigator. MM is a member of the innate immunity advisory group of the Bill & Melinda Gates Foundation, and his work is funded by the Champalimaud Foundation."
        ],
        "journal": "The Lancet",
        "volume": "395",
        "abstract": "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] Similar to patients with SARS-CoV and MERS-CoV, some patients with 2019-nCoV develop acute respiratory distress syndrome (ARDS) with characteristic pulmonary ground glass changes on imaging. In most moribund patients, 2019-nCoV infection is also associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136 In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "references": "@article{hui2019a,\n  author = {Hui, D.S.C. and Zumla, A.},\n  title = {Severe acute respiratory syndrome: historical, epidemiologic, and clinical features},\n  journal = {Infect Dis Clin North Am},\n  date = {2019},\n  volume = {33},\n  pages = {869\u201389},\n  language = {}\n}\n@article{azhar2019a,\n  author = {Azhar, E.I. and Hui, D.S.C. and Memish, Z.A. and Drosten, C. and Zumla, A.},\n  title = {The Middle East respiratory syndrome (MERS). Infect Dis Clin North},\n  journal = {Am},\n  date = {2019},\n  volume = {33},\n  pages = {891\u2013905},\n  language = {}\n}\n@incollection{huang-a,\n  author = {Huang, C. and Wang, Y. and Li, X.},\n  title = {Clinical features of patients infected with 2019 coronavirus in Wuhan, China},\n  source = {Lancet 2020; published online},\n  date = {Jan},\n  volume = {24},\n  url = {https://doi.org/10.1016/S0140-6736},\n  language = {}\n}\n@article{li2020a,\n  author = {Li, G. and Fan, Y. and Lai, Y.},\n  title = {Coronavirus infections and immune responses},\n  journal = {J Med Virol},\n  date = {2020},\n  doi = {DOI: 10.1002/ jmv.25685},\n  more-authors = {true},\n  source = {published online Jan 25},\n  language = {}\n}\n@article{channappanavar2017a,\n  author = {Channappanavar, R. and Perlman, S.},\n  title = {Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology},\n  journal = {Semin Immunopathol},\n  date = {2017},\n  volume = {39},\n  pages = {529\u201339},\n  language = {}\n}\n@misc{batawi2019a,\n  author = {Batawi, S. and Tarazan, N. and Al-Raddadi, R.},\n  title = {Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes},\n  date = {2019},\n  volume = {17},\n  pages = {101},\n  more-authors = {true},\n  language = {}\n}\n@article{ngai2010a,\n  author = {Ngai, J.C. and Ko, F.W. and Ng, S.S. and To, K.W. and Tong, M. and Hui, D.S.},\n  title = {The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status},\n  journal = {Respirology},\n  date = {2010},\n  volume = {15},\n  pages = {543\u201350},\n  language = {}\n}\n@article{zumla2016a,\n  author = {Zumla, A. and Chan, J.F. and Azhar, E.I. and Hui, D.S. and Yuen, K.Y.},\n  title = {Coronaviruses - drug discovery and therapeutic options},\n  journal = {Nat Rev Drug Discov},\n  date = {2016},\n  volume = {15},\n  pages = {327\u201347},\n  language = {}\n}\n@article{beigel2019a,\n  author = {Beigel, J.H. and Nam, H.H. and Adams, P.L.},\n  title = {Advances in respiratory virus therapeutics\u2014a meeting report from the 6th ISIRV antiviral group conference},\n  journal = {Antiviral Res},\n  date = {2019},\n  volume = {167},\n  pages = {45\u201367},\n  more-authors = {true},\n  language = {}\n}\n@article{zumla2015a,\n  author = {Zumla, A. and Azhar, E.I. and Arabi, Y.},\n  title = {Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections},\n  journal = {Int J Infect Dis},\n  date = {2015},\n  volume = {40},\n  pages = {71\u201374},\n  more-authors = {true},\n  language = {}\n}\n@article{barnard2007a,\n  author = {Barnard, D.L. and Wong, M.H. and Bailey, K.},\n  title = {Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice},\n  journal = {Antivir Chem Chemother},\n  date = {2007},\n  volume = {18},\n  pages = {125\u201332},\n  more-authors = {true},\n  language = {}\n}\n@article{horie2018a,\n  author = {Horie, S. and Gonzalez, H.E. and Laffey, J.G. and Masterson, C.H.},\n  title = {Cell therapy in acute respiratory distress syndrome},\n  journal = {J Thorac Dis},\n  date = {2018},\n  volume = {10},\n  pages = {5607\u201320},\n  language = {}\n}\n@article{davies2018a,\n  author = {Davies, R. and O\u2019Dea, K. and Gordon, A.},\n  title = {Immune therapy in sepsis: are we ready to try again?},\n  journal = {J Intensive Care Soc},\n  date = {2018},\n  volume = {19},\n  pages = {326\u201344},\n  language = {}\n}\n@article{lerias2019a,\n  author = {Lerias, JR, Paraschoudi and G, Silva and I.},\n  title = {Clinically relevant immune responses against cytomegalovirus: implications for precision medicine},\n  journal = {Int J Mol Sci},\n  date = {2019},\n  volume = {20},\n  more-authors = {true},\n  language = {}\n}\n",
        "links": [
            "http://ees.elsevier.com/",
            "http://www.thelancet.com",
            "https://www.who.int/docs/default-source/coronaviruse/",
            "https://doi.org/10.1016/"
        ],
        "pages": "e35-e36",
        "cited_by": 1,
        "references_ris": "TY  - JOUR\nAU  - Hui, D.S.C.\nAU  - Zumla, A.\nTI  - Severe acute respiratory syndrome: historical, epidemiologic, and clinical features\nT2  - Infect Dis Clin North Am\nPY  - 2019\nDA  - 2019\nVL  - 33\nSP  - 869\nEP  - 89\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Azhar, E.I.\nAU  - Hui, D.S.C.\nAU  - Memish, Z.A.\nAU  - Drosten, C.\nAU  - Zumla, A.\nTI  - The Middle East respiratory syndrome (MERS). Infect Dis Clin North\nT2  - Am\nPY  - 2019\nDA  - 2019\nVL  - 33\nSP  - 891\nEP  - 905\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Huang, C.\nAU  - Wang, Y.\nAU  - Li, X.\nTI  - Clinical features of patients infected with 2019 coronavirus in Wuhan, China\nT2  - Lancet 2020; published online\nPY  - Jan\nDA  - Jan\nVL  - 24\nUR  - https://doi.org/10.1016/S0140-6736\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, G.\nAU  - Fan, Y.\nAU  - Lai, Y.\nTI  - Coronavirus infections and immune responses\nT2  - J Med Virol\nPY  - 2020\nDA  - 2020\nDO  - 10.1002/ jmv.25685\nC1  - true\nT2  - published online Jan 25\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Channappanavar, R.\nAU  - Perlman, S.\nTI  - Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology\nT2  - Semin Immunopathol\nPY  - 2017\nDA  - 2017\nVL  - 39\nSP  - 529\nEP  - 39\nLA  - \nER  - \n\nTY  - GEN\nAU  - Batawi, S.\nAU  - Tarazan, N.\nAU  - Al-Raddadi, R.\nTI  - Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes\nPY  - 2019\nDA  - 2019\nVL  - 17\nSP  - 101\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ngai, J.C.\nAU  - Ko, F.W.\nAU  - Ng, S.S.\nAU  - To, K.W.\nAU  - Tong, M.\nAU  - Hui, D.S.\nTI  - The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status\nT2  - Respirology\nPY  - 2010\nDA  - 2010\nVL  - 15\nSP  - 543\nEP  - 50\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zumla, A.\nAU  - Chan, J.F.\nAU  - Azhar, E.I.\nAU  - Hui, D.S.\nAU  - Yuen, K.Y.\nTI  - Coronaviruses - drug discovery and therapeutic options\nT2  - Nat Rev Drug Discov\nPY  - 2016\nDA  - 2016\nVL  - 15\nSP  - 327\nEP  - 47\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Beigel, J.H.\nAU  - Nam, H.H.\nAU  - Adams, P.L.\nTI  - Advances in respiratory virus therapeutics\u2014a meeting report from the 6th ISIRV antiviral group conference\nT2  - Antiviral Res\nPY  - 2019\nDA  - 2019\nVL  - 167\nSP  - 45\nEP  - 67\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zumla, A.\nAU  - Azhar, E.I.\nAU  - Arabi, Y.\nTI  - Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections\nT2  - Int J Infect Dis\nPY  - 2015\nDA  - 2015\nVL  - 40\nSP  - 71\nEP  - 74\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Barnard, D.L.\nAU  - Wong, M.H.\nAU  - Bailey, K.\nTI  - Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice\nT2  - Antivir Chem Chemother\nPY  - 2007\nDA  - 2007\nVL  - 18\nSP  - 125\nEP  - 32\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Horie, S.\nAU  - Gonzalez, H.E.\nAU  - Laffey, J.G.\nAU  - Masterson, C.H.\nTI  - Cell therapy in acute respiratory distress syndrome\nT2  - J Thorac Dis\nPY  - 2018\nDA  - 2018\nVL  - 10\nSP  - 5607\nEP  - 20\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Davies, R.\nAU  - O\u2019Dea, K.\nAU  - Gordon, A.\nTI  - Immune therapy in sepsis: are we ready to try again?\nT2  - J Intensive Care Soc\nPY  - 2018\nDA  - 2018\nVL  - 19\nSP  - 326\nEP  - 44\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lerias, JR, Paraschoudi\nAU  - G, Silva\nAU  - I.\nTI  - Clinically relevant immune responses against cytomegalovirus: implications for precision medicine\nT2  - Int J Mol Sci\nPY  - 2019\nDA  - 2019\nVL  - 20\nC1  - true\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [],
        "figure_captions": []
    },
    "sections": {
        "funding": [
            "MM is a member of the innate immunity advisory group of the Bill & Melinda Gates Foundation, and his work is funded by the Champalimaud Foundation"
        ],
        "introduction": [
            "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal. As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17 391 confirmed cases reported to WHO.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] No specific anti-viral treatment exists. The mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. The unprecedented flurry of activity by WHO and other global public health bodies has mainly focused on preventing transmission, infection control measures, and screening of travellers. The development of vaccines has received immediate funding; however, as with SARS-CoV and MERSCoV, support for developing treatments for 2019-nCoV that reduce mortality has not been forthcoming. There is an urgent need for focusing funding and scientific investments into advancing novel therapeutic interventions for coronavirus infections.",
            "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] Similar to patients with SARS-CoV and MERS-CoV, some patients with 2019-nCoV develop acute respiratory distress syndrome (ARDS) with characteristic pulmonary ground glass changes on imaging. In most moribund patients, 2019-nCoV infection is also associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136 In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]"
        ]
    },
    "structured_content": {},
    "participants": [
        {
            "participant": "confirmed cases",
            "number": 17391,
            "context": "As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal. <mark class=\"stats\">As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17 391 confirmed cases reported to WHO.1</mark>. No specific anti-viral treatment exists"
        }
    ],
    "statistics": [],
    "keywords": [
        "host immune",
        "non effective",
        "coronavirus infections",
        "effective host",
        "aberrant non",
        "acute respiratory distress syndrome",
        "middle east respiratory syndrome",
        "immune response",
        "intensive care",
        "sars cov",
        "cytokine storm",
        "MERS",
        "SARS"
    ],
    "keyword_relevance": {
        "MERS": 0.21875,
        "acute respiratory distress syndrome": 0.1875,
        "immune response": 0.15625,
        "SARS": 0.125,
        "coronavirus infections": 0.09375,
        "intensive care": 0.0625,
        "cytokine storm": 0.0625,
        "host immune": 0.03125,
        "effective host": 0.03125,
        "aberrant non": 0.03125,
        "non effective": 0.0,
        "middle east respiratory syndrome": 0.0,
        "sars cov": 0.0
    },
    "species": [],
    "summary": [
        "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
        "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal.",
        "As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17 391 confirmed cases reported to WHO.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] No specific anti-viral treatment exists.",
        "The development of vaccines has received immediate funding; as with SARS-CoV and MERSCoV, support for developing treatments for 2019-nCoV that reduce mortality has not been forthcoming.",
        "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] Similar to patients with SARS-CoV and MERS-CoV, some patients with 2019-nCoV develop acute respiratory distress syndrome (ARDS) with characteristic pulmonary ground glass changes on imaging.",
        "2019-nCoV infection is associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136 In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "A range of existing host-directed therapies that have proven to be safe[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>\u2013<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>] could potentially be repurposed to treat 2019-nCoV infection.",
        "Several marketed drugs with excellent safety profiles such as metformin, glitazones, fibrates, sartans, and atorvastin, as well as nutrient supplements and biologics could reduce immunopathology, boost immune responses, and prevent or curb ARDS.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>\u2013<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>] Zinc and other metalcontaining formulations appear to have anti-viral activity,[<a class=\"ref-link\" id=\"c12\" href=\"#r12\">12</a>] are safe, cheap, and readily available.",
        "Ongoing trials of cellular therapies for treatment of ARDS could be expanded to treatment of seriously ill patients with 2019-nCoV infection.",
        "The isolation and short-term expansion of anti-viral directed T cells has been proven to be a lifesaving procedure in patients after autologous hematopoietic stem-cell transplantation with cytomegalovirus infection.[<a class=\"ref-link\" id=\"c15\" href=\"#r15\">15</a>] Expansion of anti-2019nCoV-specific T cells, as cellular drugs, could aid to prepare T-cell products for the adjunct treatment of patients with severe 2019-nCoV infection.",
        "AZ is coprincipal investigator of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET), funded by the European & Developing Countries Clinical Trials Partnership, supported under Horizon 2020, the EU\u2019s Framework Programme for Research and Innovation, and a National Institutes of Health Research senior investigator."
    ],
    "structured_summary": {
        "Introduction": [
            "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>].",
            "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal."
        ],
        "Results": [
            "As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17 391 confirmed cases reported to WHO.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] No specific anti-viral treatment exists.",
            "The development of vaccines has received immediate funding; as with SARS-CoV and MERSCoV, support for developing treatments for 2019-nCoV that reduce mortality has not been forthcoming.",
            "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] Similar to patients with SARS-CoV and MERS-CoV, some patients with 2019-nCoV develop acute respiratory distress syndrome (ARDS) with characteristic pulmonary ground glass changes on imaging.",
            "2019-nCoV infection is associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136 In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
            "A range of existing host-directed therapies that have proven to be safe[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>\u2013<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>] could potentially be repurposed to treat 2019-nCoV infection.",
            "Several marketed drugs with excellent safety profiles such as metformin, glitazones, fibrates, sartans, and atorvastin, as well as nutrient supplements and biologics could reduce immunopathology, boost immune responses, and prevent or curb ARDS.[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>\u2013<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>] Zinc and other metalcontaining formulations appear to have anti-viral activity,[<a class=\"ref-link\" id=\"c12\" href=\"#r12\">12</a>] are safe, cheap, and readily available.",
            "Ongoing trials of cellular therapies for treatment of ARDS could be expanded to treatment of seriously ill patients with 2019-nCoV infection."
        ],
        "Conclusion": [
            "The isolation and short-term expansion of anti-viral directed T cells has been proven to be a lifesaving procedure in patients after autologous hematopoietic stem-cell transplantation with cytomegalovirus infection.[<a class=\"ref-link\" id=\"c15\" href=\"#r15\">15</a>] Expansion of anti-2019nCoV-specific T cells, as cellular drugs, could aid to prepare T-cell products for the adjunct treatment of patients with severe 2019-nCoV infection.",
            "AZ is coprincipal investigator of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET), funded by the European & Developing Countries Clinical Trials Partnership, supported under Horizon 2020, the EU\u2019s Framework Programme for Research and Innovation, and a National Institutes of Health Research senior investigator."
        ]
    },
    "reference_links": [
        {
            "id": "2",
            "alt_id": "Hui_2019_a",
            "entry": "2 Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am 2019; 33: 869\u201389.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hui%2C%20D.S.C.%20Zumla%2C%20A.%20Severe%20acute%20respiratory%20syndrome%3A%20historical%2C%20epidemiologic%2C%20and%20clinical%20features%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hui%2C%20D.S.C.%20Zumla%2C%20A.%20Severe%20acute%20respiratory%20syndrome%3A%20historical%2C%20epidemiologic%2C%20and%20clinical%20features%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hui%2C%20D.S.C.%20Zumla%2C%20A.%20Severe%20acute%20respiratory%20syndrome%3A%20historical%2C%20epidemiologic%2C%20and%20clinical%20features%202019"
        },
        {
            "id": "3",
            "alt_id": "Azhar_et+al_2019_a",
            "entry": "3 Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East respiratory syndrome (MERS). Infect Dis Clin North Am 2019; 33: 891\u2013905.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Azhar%2C%20E.I.%20Hui%2C%20D.S.C.%20Memish%2C%20Z.A.%20Drosten%2C%20C.%20The%20Middle%20East%20respiratory%20syndrome%20%28MERS%29.%20Infect%20Dis%20Clin%20North%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Azhar%2C%20E.I.%20Hui%2C%20D.S.C.%20Memish%2C%20Z.A.%20Drosten%2C%20C.%20The%20Middle%20East%20respiratory%20syndrome%20%28MERS%29.%20Infect%20Dis%20Clin%20North%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Azhar%2C%20E.I.%20Hui%2C%20D.S.C.%20Memish%2C%20Z.A.%20Drosten%2C%20C.%20The%20Middle%20East%20respiratory%20syndrome%20%28MERS%29.%20Infect%20Dis%20Clin%20North%202019"
        },
        {
            "id": "4",
            "alt_id": "Huang_et+al_Jan_a",
            "entry": "4 Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 coronavirus in Wuhan, China. Lancet 2020; published online Jan 24. https://doi.org/10.1016/ S0140-6736(20)30183-5.",
            "url": "https://doi.org/10.1016/S0140-6736(20)30183-5",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Huang%20C%20Wang%20Y%20Li%20X%20Clinical%20features%20of%20patients%20infected%20with%202019%20coronavirus%20in%20Wuhan%20China%20Lancet%202020%20published%20online%20Jan%2024%20httpsdoiorg101016%20S0140673620301835",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Huang%20C%20Wang%20Y%20Li%20X%20Clinical%20features%20of%20patients%20infected%20with%202019%20coronavirus%20in%20Wuhan%20China%20Lancet%202020%20published%20online%20Jan%2024%20httpsdoiorg101016%20S0140673620301835"
        },
        {
            "id": "5",
            "alt_id": "Li_et+al_2020_a",
            "entry": "5 Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol 2020; published online Jan 25. DOI:10.1002/ jmv.25685.",
            "crossref": "https://dx.doi.org/10.1002/jmv.25685",
            "scite": "https://scite.ai/reports/10.1002/jmv.25685",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1002/jmv.25685"
        },
        {
            "id": "6",
            "alt_id": "Channappanavar_2017_a",
            "entry": "6 Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39: 529\u201339.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Channappanavar%2C%20R.%20Perlman%2C%20S.%20Pathogenic%20human%20coronavirus%20infections%3A%20causes%20and%20consequences%20of%20cytokine%20storm%20and%20immunopathology%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Channappanavar%2C%20R.%20Perlman%2C%20S.%20Pathogenic%20human%20coronavirus%20infections%3A%20causes%20and%20consequences%20of%20cytokine%20storm%20and%20immunopathology%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Channappanavar%2C%20R.%20Perlman%2C%20S.%20Pathogenic%20human%20coronavirus%20infections%3A%20causes%20and%20consequences%20of%20cytokine%20storm%20and%20immunopathology%202017"
        },
        {
            "id": "7",
            "alt_id": "Batawi_et+al_2019_a",
            "entry": "7 Batawi S, Tarazan N, Al-Raddadi R, et al. Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health Qual Life Outcomes 2019; 17: 101.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Batawi%2C%20S.%20Tarazan%2C%20N.%20Al-Raddadi%2C%20R.%20Quality%20of%20life%20reported%20by%20survivors%20after%20hospitalization%20for%20Middle%20East%20respiratory%20syndrome%20%28MERS%29.%20Health%20Qual%20Life%20Outcomes%202019"
        },
        {
            "id": "8",
            "alt_id": "Ngai_et+al_2010_a",
            "entry": "8 Ngai JC, Ko FW, Ng SS, To KW, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15: 543\u201350.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ngai%2C%20J.C.%20Ko%2C%20F.W.%20Ng%2C%20S.S.%20To%2C%20K.W.%20The%20long-term%20impact%20of%20severe%20acute%20respiratory%20syndrome%20on%20pulmonary%20function%2C%20exercise%20capacity%20and%20health%20status%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ngai%2C%20J.C.%20Ko%2C%20F.W.%20Ng%2C%20S.S.%20To%2C%20K.W.%20The%20long-term%20impact%20of%20severe%20acute%20respiratory%20syndrome%20on%20pulmonary%20function%2C%20exercise%20capacity%20and%20health%20status%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ngai%2C%20J.C.%20Ko%2C%20F.W.%20Ng%2C%20S.S.%20To%2C%20K.W.%20The%20long-term%20impact%20of%20severe%20acute%20respiratory%20syndrome%20on%20pulmonary%20function%2C%20exercise%20capacity%20and%20health%20status%202010"
        },
        {
            "id": "9",
            "alt_id": "Zumla_et+al_2016_a",
            "entry": "9 Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327\u201347.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zumla%2C%20A.%20Chan%2C%20J.F.%20Azhar%2C%20E.I.%20Hui%2C%20D.S.%20Coronaviruses%20-%20drug%20discovery%20and%20therapeutic%20options%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zumla%2C%20A.%20Chan%2C%20J.F.%20Azhar%2C%20E.I.%20Hui%2C%20D.S.%20Coronaviruses%20-%20drug%20discovery%20and%20therapeutic%20options%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zumla%2C%20A.%20Chan%2C%20J.F.%20Azhar%2C%20E.I.%20Hui%2C%20D.S.%20Coronaviruses%20-%20drug%20discovery%20and%20therapeutic%20options%202016"
        },
        {
            "id": "10",
            "alt_id": "Beigel_et+al_2019_a",
            "entry": "10 Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics\u2014a meeting report from the 6th ISIRV antiviral group conference. Antiviral Res 2019; 167: 45\u201367.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Beigel%2C%20J.H.%20Nam%2C%20H.H.%20Adams%2C%20P.L.%20Advances%20in%20respiratory%20virus%20therapeutics%E2%80%94a%20meeting%20report%20from%20the%206th%20ISIRV%20antiviral%20group%20conference%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Beigel%2C%20J.H.%20Nam%2C%20H.H.%20Adams%2C%20P.L.%20Advances%20in%20respiratory%20virus%20therapeutics%E2%80%94a%20meeting%20report%20from%20the%206th%20ISIRV%20antiviral%20group%20conference%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Beigel%2C%20J.H.%20Nam%2C%20H.H.%20Adams%2C%20P.L.%20Advances%20in%20respiratory%20virus%20therapeutics%E2%80%94a%20meeting%20report%20from%20the%206th%20ISIRV%20antiviral%20group%20conference%202019"
        },
        {
            "id": "11",
            "alt_id": "Zumla_et+al_2015_a",
            "entry": "11 Zumla A, Azhar EI, Arabi Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the Middle East respiratory syndrome coronavirus infections. Int J Infect Dis 2015; 40: 71\u201374.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zumla%2C%20A.%20Azhar%2C%20E.I.%20Arabi%2C%20Y.%20Host-directed%20therapies%20for%20improving%20poor%20treatment%20outcomes%20associated%20with%20the%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infections%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zumla%2C%20A.%20Azhar%2C%20E.I.%20Arabi%2C%20Y.%20Host-directed%20therapies%20for%20improving%20poor%20treatment%20outcomes%20associated%20with%20the%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infections%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zumla%2C%20A.%20Azhar%2C%20E.I.%20Arabi%2C%20Y.%20Host-directed%20therapies%20for%20improving%20poor%20treatment%20outcomes%20associated%20with%20the%20Middle%20East%20respiratory%20syndrome%20coronavirus%20infections%202015"
        },
        {
            "id": "12",
            "alt_id": "Barnard_et+al_2007_a",
            "entry": "12 Barnard DL, Wong MH, Bailey K, et al. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antivir Chem Chemother 2007; 18: 125\u201332.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Barnard%2C%20D.L.%20Wong%2C%20M.H.%20Bailey%2C%20K.%20Effect%20of%20oral%20gavage%20treatment%20with%20ZnAL42%20and%20other%20metallo-ion%20formulations%20on%20influenza%20A%20H5N1%20and%20H1N1%20virus%20infections%20in%20mice%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Barnard%2C%20D.L.%20Wong%2C%20M.H.%20Bailey%2C%20K.%20Effect%20of%20oral%20gavage%20treatment%20with%20ZnAL42%20and%20other%20metallo-ion%20formulations%20on%20influenza%20A%20H5N1%20and%20H1N1%20virus%20infections%20in%20mice%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Barnard%2C%20D.L.%20Wong%2C%20M.H.%20Bailey%2C%20K.%20Effect%20of%20oral%20gavage%20treatment%20with%20ZnAL42%20and%20other%20metallo-ion%20formulations%20on%20influenza%20A%20H5N1%20and%20H1N1%20virus%20infections%20in%20mice%202007"
        },
        {
            "id": "13",
            "alt_id": "Horie_et+al_2018_a",
            "entry": "13 Horie S, Gonzalez HE, Laffey JG, Masterson CH. Cell therapy in acute respiratory distress syndrome. J Thorac Dis 2018; 10: 5607\u201320.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Horie%2C%20S.%20Gonzalez%2C%20H.E.%20Laffey%2C%20J.G.%20Masterson%2C%20C.H.%20Cell%20therapy%20in%20acute%20respiratory%20distress%20syndrome%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Horie%2C%20S.%20Gonzalez%2C%20H.E.%20Laffey%2C%20J.G.%20Masterson%2C%20C.H.%20Cell%20therapy%20in%20acute%20respiratory%20distress%20syndrome%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Horie%2C%20S.%20Gonzalez%2C%20H.E.%20Laffey%2C%20J.G.%20Masterson%2C%20C.H.%20Cell%20therapy%20in%20acute%20respiratory%20distress%20syndrome%202018"
        },
        {
            "id": "14",
            "alt_id": "Davies_et+al_2018_a",
            "entry": "14 Davies R, O\u2019Dea K, Gordon A. Immune therapy in sepsis: are we ready to try again? J Intensive Care Soc 2018; 19: 326\u201344.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Davies%2C%20R.%20O%E2%80%99Dea%2C%20K.%20Gordon%2C%20A.%20Immune%20therapy%20in%20sepsis%3A%20are%20we%20ready%20to%20try%20again%3F%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Davies%2C%20R.%20O%E2%80%99Dea%2C%20K.%20Gordon%2C%20A.%20Immune%20therapy%20in%20sepsis%3A%20are%20we%20ready%20to%20try%20again%3F%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Davies%2C%20R.%20O%E2%80%99Dea%2C%20K.%20Gordon%2C%20A.%20Immune%20therapy%20in%20sepsis%3A%20are%20we%20ready%20to%20try%20again%3F%202018"
        },
        {
            "id": "15",
            "alt_id": "Lerias_et+al_2019_a",
            "entry": "15 Lerias JR, Paraschoudi G, Silva I, et al. Clinically relevant immune responses against cytomegalovirus: implications for precision medicine. Int J Mol Sci 2019; 20: 1986.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lerias%2C%20JR%2C%20Paraschoudi%20G%2C%20Silva%20I.%20Clinically%20relevant%20immune%20responses%20against%20cytomegalovirus%3A%20implications%20for%20precision%20medicine%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lerias%2C%20JR%2C%20Paraschoudi%20G%2C%20Silva%20I.%20Clinically%20relevant%20immune%20responses%20against%20cytomegalovirus%3A%20implications%20for%20precision%20medicine%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lerias%2C%20JR%2C%20Paraschoudi%20G%2C%20Silva%20I.%20Clinically%20relevant%20immune%20responses%20against%20cytomegalovirus%3A%20implications%20for%20precision%20medicine%202019"
        }
    ],
    "facts": [
        "aberrant non-effective host immune responses that are associated with severe lung pathology",
        "2019-nCoV infection is associated with a cytokine storm",
        "which is characterised by increased plasma concentrations of interleukins 2",
        "excessive immune responses lead to long-term lung damage and fibrosis",
        "The number of confirmed cases of the 2019 novel coronavirus reported to WHO continues to rise",
        "of 17 391 confirmed cases reported to WHO.[1",
        "other global public health bodies has mainly focused on preventing transmission",
        "Ongoing trials of cellular therapies for treatment of ARDS could be expanded to treatment of seriously ill patients"
    ],
    "claims": [],
    "findings": [],
    "processes": [],
    "key_statements": [
        "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>]",
        "2019-nCoV infection is associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136",
        "In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "Ongoing trials of cellular therapies for treatment of acute respiratory distress syndrome could be expanded to treatment of seriously ill patients with 2019-nCoV infection"
    ],
    "top_statements": [
        "The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]",
        "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>\u2013<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>]",
        "2019-nCoV infection is associated with a cytokine storm, which is characterised by increased plasma concentrations of interleukins 2, 7, and 10, granulo\u00ad cyte-colony stimulating factor, interferon-\u03b3-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and tumour necrosis factor \u03b1.2\u20136",
        "In those who survive intensive care, these aberrant and excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life.[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>,<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]",
        "Ongoing trials of cellular therapies for treatment of acute respiratory distress syndrome could be expanded to treatment of seriously ill patients with 2019-nCoV infection"
    ],
    "headline": "All three coronaviruses induce excessive and aberrant non-effective host immune responses that are associated with severe lung pathology, leading to death.2\u20134",
    "contexts": [],
    "abbreviations": {
        "ARDS": "acute respiratory distress syndrome"
    }
}
